Evidence map›Paper›PMID 40502853›Full record

ArticleClinical and translational radiation oncology2025

A GORTEC survey on low-risk CTV-P2 delineation in head and neck cancers.

Michel Lapeyre, Yoann Pointreau, Marc Alfonsi, Pierre Boisselier, Julian Biau, Pierre Blanchard, Joël Castelli, Pierre Graff, Florence Huguet, Laurent Martin and 5 more

Abstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michel LapeyreDepartment of Radiation Therapy, Jean Perrin Centre, 58 Rue Montalembert, BP 5026, 63011 Clermont Ferrand Cedex 1, France.
Yoann PointreauDepartment of Radiation Therapy, Inter-Regional Institute of Oncology (ILC, Institut inter-régionaL de Cancérologie), Jean Bernard Centre, Sarthe Oncology Centre 64 Rue de Degré 72000 Le Mans, France.
Marc AlfonsiDepartment of Radiation Therapy, Sainte-Catherine Institute - Avignon-Provence Cancer Institute, CS 80005, 250 Chemin de Baigne Pieds, 84918 Avignon Cedex 9, France.
Pierre BoisselierDepartment of Radiation Therapy, Montpellier Regional Cancer Institute, Parc Euromédecine, 208 rue des Apothicaires, 34090 Montpellier, France.
Julian BiauDepartment of Radiation Therapy, Jean Perrin Centre, 58 Rue Montalembert, BP 5026, 63011 Clermont Ferrand Cedex 1, France.
Pierre BlanchardDepartment of Radiation Therapy, Gustave Roussy Institute, 114 Rue Edouard Vaillant, 94805 Villejuif, France.
Joël CastelliDepartment of Radiation Therapy, Eugène Marquis Centre, Av. de la Bataille Flandres-Dunkerque CS 44229, 35000 Rennes, France.
Pierre GraffDepartment of Radiation Therapy, Curie Institute, 26 rue d'Ulm, 75248 Paris Cedex 05, France.
Florence HuguetDepartment of Radiation Therapy, Tenon Hospital, 4 rue de la Chine, 75020 Paris, France.
Laurent MartinGuillaume Le Conquérant Centre, 61 Rue Denfert Rochereau, 76600 Le Havre, France.
Séverine RacadotDepartment of Radiation Therapy, Léon Berard Centre, 28 Rue Laennec, 69008 Lyon, France.
Xu Shan SunDepartment of Radiation Therapy, Franche-Comté North Hospital in Montbéliard & Besançon CHRU (Centre hospitalier régional universitaire [Regional University Hospital]), 1 Rue Henri Becquerel, 25200 Montbéliard, France.
Yungan TaoDepartment of Radiation Therapy, Gustave Roussy Institute, 114 Rue Edouard Vaillant, 94805 Villejuif, France.
Jean BourhisDepartment of Radiation Therapy, Lausanne University Hospital (CHUV, Centre Hospitalier Universitaire Vaudois), Rue du Bugnon 46, 1005 Lausanne, Switzerland.
Juliette ThariatDepartment of Radiation Therapy, Comprehensive Cancer Centre François Baclesse, 3 Avenue du General Harris, 14000 Caen, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: An international consensus was established in 2018 to standardise practice using geometric (5 + 5 mm) expansion around GTV-P for definitive radiotherapy of squamous cell carcinomas of the head and neck (HNC). The GORTEC (French HNC Oncology and Radiotherapy Group) conducted a survey to assess the level of agreement about CTV-P2 delineation using a "formalised consensus method". Methods: The 32 proposals of the 2018 consensus on CTV-P2 and 6 additional GORTEC proposals were submitted to 13 GORTEC radiation oncologists (RO). Proposals were rated as "suitable" for median scores ≥7, "unsuitable" for scores ≤3.5 or "uncertain." The degree of agreement was high (≥85 %), moderate (75-84 %) or low (<75 %). Suitable proposals were reviewed by 40 other RO for final recommendations. Results: The 2018 proposals were "uncertain" with low degrees of agreement (41.5-69 %), except for T1 tumors, which had 89 % agreement. Five out of 6 GORTEC proposals were "suitable" and one "uncertain." The final recommendation was "suitable and to be retained" by 97.5 % of RO, as follows: To obtain CTV-P2, GORTEC recommends applying a "geo-anatomical" approach. Using the geometric concept, 10 mm-isotropic margins are applied to the GTV, for all locations but the hypopharynx (10 mm antero-posterior, laterally and 15 mm craniocaudally). CTV-P2 is further modified using the anatomical concept (anatomical barriers, dissemination routes) and accounting the benefit/risk balance and proximity of organs at risk. Conclusion: The GORTEC survey derived from the 2018 international CTV-Ps delineation consensus suggests a "geo-anatomical" approach for the delineation of CTV-P2 in HNC.

Indexed as

CancerConsensus GuidelinesCTV definitionDelineationHead and neck

Identifiers

PMID40502853
PMCPMC12152911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.